MANGALAMPharmaceuticals
Mangalam Drugs and Organics Ltd — Profit & Loss Statement
₹27.15
-4.91%
Mangalam Drugs and Organics Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| EBITDA | 36.33 Cr | 17.49 Cr | 22.12 Cr | 45.18 Cr | — |
| EBIT | 19.72 Cr | 2.84 Cr | 11.13 Cr | 34.94 Cr | — |
| Net Interest Income | -14.93 Cr | -13.92 Cr | -12.45 Cr | -11.16 Cr | — |
| Interest Expense | 14.93 Cr | 13.92 Cr | 8.92 Cr | 7.20 Cr | — |
| Normalized Income | 6.72 Cr | -9.07 Cr | 1.27 Cr | 19.59 Cr | — |
| Net Income From Continuing And Discontinued Operation | 6.72 Cr | -9.07 Cr | 1.27 Cr | 19.66 Cr | — |
| Total Expenses | 298.36 Cr | 364.61 Cr | 351.38 Cr | 408.60 Cr | — |
| Diluted Average Shares | 1.58 Cr | 1.58 Cr | 1.58 Cr | 1.58 Cr | — |
| Basic Average Shares | 1.58 Cr | 1.58 Cr | 1.58 Cr | 1.58 Cr | — |
| Diluted EPS | 4.25 | -5.73 | 0.80 | 12.42 | — |
| Basic EPS | 4.25 | -5.73 | 0.80 | 12.42 | — |
| Diluted NI Availto Com Stockholders | 6.72 Cr | -9.07 Cr | 1.27 Cr | 19.66 Cr | — |
| Net Income Common Stockholders | 6.72 Cr | -9.07 Cr | 1.27 Cr | 19.66 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 6.72 Cr | -9.07 Cr | 1.27 Cr | 19.66 Cr | — |
| Net Income Including Noncontrolling Interests | 6.72 Cr | -9.07 Cr | 1.27 Cr | 19.66 Cr | — |
| Net Income Extraordinary | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income Continuous Operations | 6.72 Cr | -9.07 Cr | 1.27 Cr | 19.66 Cr | — |
| Tax Provision | -1.93 Cr | -2.00 Cr | 0.94 Cr | 8.08 Cr | — |
| Pretax Income | 4.79 Cr | -11.07 Cr | 2.21 Cr | 27.73 Cr | — |
| Other Non Operating Income Expenses | 0.50 Cr | 0.10 Cr | 0.08 Cr | 0.03 Cr | — |
| Special Income Charges | 0.00 | 0.00 | -33000.00 | 67000.00 | — |
| Net Non Operating Interest Income Expense | -14.93 Cr | -13.92 Cr | -12.45 Cr | -11.16 Cr | — |
| Interest Expense Non Operating | 14.93 Cr | 13.92 Cr | 8.92 Cr | 7.20 Cr | — |
| Operating Income | 19.22 Cr | 2.75 Cr | 14.59 Cr | 38.76 Cr | — |
| Operating Expense | 130.99 Cr | 120.10 Cr | 55.56 Cr | 59.98 Cr | — |
| Other Operating Expenses | 74.45 Cr | 67.61 Cr | -0.10 Cr | 58.12 Cr | — |
| Depreciation And Amortization In Income Statement | 16.61 Cr | 14.65 Cr | 10.99 Cr | 10.25 Cr | — |
| Depreciation Income Statement | 16.61 Cr | 14.65 Cr | 10.99 Cr | 10.25 Cr | — |
| Gross Profit | 150.21 Cr | 122.84 Cr | 70.15 Cr | 98.74 Cr | — |
| Cost Of Revenue | 167.37 Cr | 244.51 Cr | 295.82 Cr | 348.62 Cr | — |
| Total Revenue | 317.58 Cr | 367.35 Cr | 365.97 Cr | 447.37 Cr | — |
| Operating Revenue | 317.58 Cr | 367.35 Cr | 365.97 Cr | 447.37 Cr | — |
| Tax Effect Of Unusual Items | 0.00 | 0.00 | -9900.00 | 0.03 Cr | — |
| Tax Rate For Calcs | 0.30 | 0.18 | 0.30 | 0.29 | — |
| Normalized EBITDA | 36.33 Cr | 17.49 Cr | 22.13 Cr | 45.09 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | -33000.00 | 0.10 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | -33000.00 | 0.10 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 6.72 Cr | -9.07 Cr | 1.27 Cr | 19.66 Cr | — |
| Reconciled Depreciation | 16.61 Cr | 7.49 Cr | 10.99 Cr | 10.25 Cr | — |
| Reconciled Cost Of Revenue | 167.37 Cr | 244.51 Cr | 295.82 Cr | 348.62 Cr | — |
| Interest Income | — | 0.10 Cr | 0.30 Cr | 0.00 | 0.62 Cr |
| Rent Expense Supplemental | — | 0.55 Cr | 0.60 Cr | 0.81 Cr | 0.98 Cr |
| Minority Interests | — | 0.00 | 0.00 | — | — |
| Other Special Charges | — | 0.05 Cr | 33000.00 | -67000.00 | 0.07 Cr |
| Total Other Finance Cost | — | 3.51 Cr | 3.83 Cr | 3.96 Cr | 3.01 Cr |
| Interest Income Non Operating | — | 0.10 Cr | 0.30 Cr | 0.00 | 0.62 Cr |
| Selling General And Administration | — | 16.45 Cr | 15.44 Cr | 15.06 Cr | 13.43 Cr |
| Selling And Marketing Expense | — | 6.93 Cr | 6.19 Cr | 7.29 Cr | 7.18 Cr |
| General And Administrative Expense | — | 9.51 Cr | 9.25 Cr | 7.77 Cr | 6.24 Cr |
| Rent And Landing Fees | — | 0.55 Cr | 0.60 Cr | 0.81 Cr | 0.98 Cr |
| Research And Development | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Mangalam Drugs and Organics Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.